[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, modified vaccinia Ankara (MVA) is considered a leading candidate for an alternative smallpox vaccine. Document [0] states that MVA is suggested as a leading candidate for an alternative smallpox vaccine. Document [2] compares the efficacy of MVA alone and in combination with classical vaccinia virus-based vaccines and concludes that MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus. Document [3] states that MVA is broadly similar to Lister vaccine in terms of longevity and efficacy of immunity induced. Document [8] mentions that IMVAMUNE, which is based on MVA, is being developed as a potential prevention of smallpox infection. Document [9] proposes MVA as an immediate solution for vaccination of high-risk individuals. Document [11] characterizes the immunogenicity of MVA in HIV-1-infected individuals and suggests it as a safer vaccine for immunocompromised individuals. Document [12] describes MVA as a recombinant viral vector to produce vaccines against infectious diseases, including smallpox. Document [15] states that MVA is licensed as a third-generation vaccine against smallpox. Document [23] reports that MVA vaccine protected against variola infection in a phase 3 efficacy trial. Based on this information, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]